Keryx Biopharmaceuticals (NASDAQ:KERX)

buy sell

Russell 2000 Rebalance May Bring Huge Buying in Key Stocks

Typically when any major index does a rebalancing, there is a large amount of buying and selling that takes place as the index resets to the new percentage assignments for ...
Read Full Story »
Organovo 3D bioprinter

Oppenheimer Sees Five Biotech Stocks to Buy With Potential 50% Upside, or More

After a tremendous run the past three years, it appears that parts of the biotech sector may be poised for another year of gains in 2014. Many of the firms ...
Read Full Story »
biotech

Four Big Healthy Biotech Gainers, One Big Loser

Biotech and certain aspects of the health care and life sciences sector can often see incredible surges from day to day. The group can also witness many implosions on bad ...
Read Full Story »
Wall St Bull statue

Top Analyst Upgrades and Stocks to Buy: Adobe, Gevo, Keryx, Teva and More

Investors and traders are often on the hunt for fresh research ideas that will lead to higher income or more profits in this choppy stock and volatile market. 24/7 Wall ...
Read Full Story »
biotech

PropThink Biotech Stocks With Big Upside Potential

The world of biotech investing is always a difficult one. Often a binary event, such as a U.S. Food and Drug Administration (FDA) approval or a life-saving capital raise is ...
Read Full Story »
Wall St Bull statue

Thirteen Stocks Expected to Rise 40% to 100% — or More

Investors and traders alike always seem to be on the lookout for new speculative investment ideas that can generate massive long-term or short-term gains. While investors get to see many ...
Read Full Story »
biotech

PropThink Analyst Finds Five Cheap Biotech Stocks to Buy

Biotech investing has always proven to be a slippery slope. It is one thing to own one of the large-cap biotech stocks, but it can be a challenge when looking for ...
Read Full Story »
Bull and Bear figures

24/7 Wall St. Closing Bell — February 1, 2013: Markets Stronger on Economic Data (VZ, MA, EPD, STZ, UPS, BYI, GDOT, WYNN, CVX, XOM, MAT, MRK, NOV, TSN, CYOU, GCI, HUM, GOLD, RCL, SPG, CLX, ZTS, KERX, FB)

U.S. equity markets opened higher this morning on the heels of a solid report on U.S. nonfarm payrolls, which rose less than expected but on top of a large upward ...
Read Full Story »
Bull and Bear figures

24/7 Wall St. Closing Bell — January 29, 2013: Markets Shake Off Slow Start, Post Gains (STX, TSN, SBUX, ANF, CAT, YHOO, STX, STLD, BSX, DHI, F, BTU, PFE, VLO, AMZN, BRCM, RYL, RHI, ADT, LLL, PSX, NOC, SO, KERX, VMW, OCZ)

U.S. equity markets opened slightly lower this morning following not-much in the way of new data and a wait-and-see attitude until tomorrow’s meeting announcement from the FOMC, which began a ...
Read Full Story »
Traders

Today’s Market Winners and Losers

The stock market is mixed Tuesday, with the Dow Jones Industrial Average up 0.27%, the Nasdaq down 0.35% and the S&P 500 up 0.13%. Today's winners are a biopharmaceutical company that ...
Read Full Story »
Bull and Bear figures

24/7 Wall St. Closing Bell — January 28, 2013: Markets Open Mixed, Close Nearly Flat (AKS, HEP, NWSA, FB, BBY, CAT, ROP, SIFY, BIIB, YHOO, STX, VMW, STLD, BSX, DHI, F, BTU, PFE, VLO, KERX, JOSB, HLF)

U.S. equity markets opened mixed this morning on relatively little new data. In Europe, Italian consumer confidence rose more than expected and Germany auctioned 12-month bills at a positive yield ...
Read Full Story »
health care

Keryx Gets Back on the Map

Keryx Biopharmaceuticals Inc. (NASDAQ: KERX) has not been a household name in biotech investing, but the move on news on Monday has put the company on the map. After shares ...
Read Full Story »
Future-market-trading

Today’s Market Winners and Losers

The stock market is down Monday, with the Dow Jones Industrial Average down 0.20%, the Nasdaq down 0.04% and the S&P 500 down 0.39%. Today's sole winner is a pharmaceutical company ...
Read Full Story »

24/7 Wall St. Closing Bell (AMZN, GRPN, RIO, TXN, GM, DDMG, CLRO, GPN, CMVT, ISCA, VRNG, WG, KERX, PNCL)

Markets opened lower this morning but managed to recover fairly quickly following a report on robust manufacturing growth (our coverage here). The report on construction spending came in weaker than ...
Read Full Story »

Keryx Drug Fails Test, Shares Plunge (KERX)

Keryx Biopharmaceuticals Inc. (NASDAQ: KERX) this morning announced that its colorectal cancer treatment did no better than placebo in a Phase 3 trial. The company said it will evaluate whether ...
Read Full Story »